Abstract 116P
Background
RAS mutation has become an important part of assessment of patients with colorectal cancer (CRC), but its role in colorectal cancer patients with initially unresectable liver metastases has yet to be elaborated. We aim to assess the role of RAS mutation on convertion of patients with initially unresectable colorectal liver metastases (CLMs).
Methods
We identified CRC patients who initially with unresectable liver metastases during January 2012 to December 2017 in Zhongshan Hospital Fudan University. The association between RAS status of primary tumor and characteristics of patients were analyzed. Conversion rates was determined.
Results
A total of consecutive 433 CLM patients with available RAS status were evaluated in this study, KRAS mutation rates was 41.5%, BRAF was 6.7% and NRAS was 1.6%. 258 patients were RAS wild type and 185 patients were mutant. RAS mutation were associated with right colon cancer (P = 0.006) and lymph node metastasis (P = 0.017). Among RAS wild type patients, 56.2% (145/258) received Cetuximab plus chemotherapy treatment, 7.8% (20/258) received Bevacizumab plus chemotherapy and the others received chemotherapy only. Among RAS mutant patients, 50.8% (94/185) received Bevacizumab plus chemotherapy and 49.2% (91/185) received chemotherapy only. RAS wild type patients had a better objective response rate (52.3% vs 37.3%, p = 0.011) and higher conversion rate (24.0% vs 12.4%, P = 0.002) compare with RAS mutant patients. For RAS wild type group, patients with Cetuximab plus chemotherapy, Bevacizumab plus chemotherapy and chemotherapy only have a conversion resection rate of 31.5% ,20% and 14.3% respectively P = 0.05 for RAS mutation group, Bevacizumab plus chemotherapy had a similar conversion resection rate compared with chemotherapy only (12.6% VS 11.3%, P = 0.815).
Conclusions
RAS wild type indicated a better conversion rate for patients with initially unresectable colorectal liver metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract